Progress in the development of new drugs in Alzheimer's disease

Journal of Nutrition, Health and Aging

Volumn 15, Issue 1, 2011, Pages 45-57

  Piau, Antoine ^a,c   Nourhashemi F ^a,b   Hein, C ^a   Caillaud, C ^a   Vellas, B ^a,b  

^a Hopitaux de Toulouse   (France)

^b INSERM   (France)

^c TOULOUSE UNIVERSITY HOSPITAL   (France)

Author keywords

Alzheimer's disease; clinical trials; disease modifying therapies

Indexed keywords

2,3 DIHYDRO 3,4 CYCLOPENTANO 1,2,4 BENZOTHIADIAZINE 1,1 DIOXIDE; 2,4 THIAZOLIDINEDIONE DERIVATIVE; 6 QUINOXALINECARBOXYLIC ACID PIPERIDIDE; ALEPLASININ; ALZHEIMER DISEASE VACCINE; AMYLOID BETA PROTEIN; ANTIOXIDANT; BAPINEUZUMAB; BEGACESTAT; CURCUMIN; CYCLOPHOSPHAMIDE; ETANERCEPT; FK 962; FLURBIPROFEN; GLUTAMIC ACID; GSK 188909; GSK 933776A; HOMOTAURINE; IBUPROFEN; INDOMETACIN; INSULIN; LETEPRINIM; MEMANTINE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; N [2 [4 (4 CYANOPHENYL)PHENYL]PROPYL] 2 PROPANESULFONAMIDE; N [2 [4' (2 METHYLSULFONAMIDOETHYL)BIPHENYL 4 YL]PROPYL] 2 PROPANESULFONAMIDE; NAPROXEN; NERAMEXANE; NEUROTROPHIN; NEW DRUG; NONSTEROID ANTIINFLAMMATORY AGENT; PAI 1; PF 04360365; PF 4494700; PHENSERINE; PLY 2062430; RESVERATROL; ROFECOXIB; SECRETASE; SEMAGACESTAT; STATIN; TARENFLURBIL; TAU PROTEIN; UNCLASSIFIED DRUG; UNINDEXED DRUG; XALIPRODEN;

ACTIVE IMMUNIZATION; ALZHEIMER DISEASE; ARTICLE; CARDIOVASCULAR DISEASE; CELL THERAPY; DISEASE COURSE; DRUG DEVELOPMENT; HORMONAL THERAPY; HUMAN; NONHUMAN; PASSIVE IMMUNIZATION; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN DEGRADATION; UNSPECIFIED SIDE EFFECT;

EID: 85027946376     PISSN: 12797707     EISSN: 17604788     Source Type: Journal    
DOI: 10.1007/s12603-011-0012-x     Document Type: Article

References (252)

1. R. Brookmeyer E. Johnson G. Ziegler, et al. 2007 Forecasting the global burden of Alzheimer's disease Alzheimers Dement 3 186 191 19595937 10.1016/j.jalz.2007.04.381 (Pubitemid 46825511)
2. Birks J. Cholinesterase inhibitors for Alzheimer's disease. Cochrane Database of Systematic Reviews 2006;1:CD005593.
3. McShane R, Areosa Sastre A, Minakaran N. Memantine for dementia. Cochrane Database of Systematic Reviews 2006;2: CD003154.
4. P. Raina P. Santaguida A. Ismaila, et al. 2008 Effectiveness of cholinesterase inhibitors and memantine for treating dementia: evidence review for a clinical practice guideline Ann Intern Med 148 379 397 18316756 (Pubitemid 351665469)
5. T. Iwatsubo A. Odaka N. Suzuki, et al. 1994 Visualization of A beta 42(43) and A beta 40 in senile plaques with end-specific A beta monoclonals: evidence that an initially deposited species is A beta 42(43) Neuron 13 45 53 1:CAS:528:DyaK2cXlsFCkt74%3D 8043280 10.1016/0896-6273(94)90458-8
6. J. Hardy 2006 Has the amyloid cascade hypothesis for Alzheimer's disease been proved? Curr Alzheimer Res 3 71 73 1:CAS:528:DC%2BD28XisVant7o%3D 16472206 10.2174/156720506775697098
7. J. Hardy D.J. Selkoe 2002 The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics Science 297 353 356 1:CAS:528:DC%2BD38Xls1Cju7s%3D 12130773 10.1126/science.1072994 (Pubitemid 34790756)
8. J. Ghiso B. Frangione 2001 Cerebral amyloidosis, amyloid angiopathy, and their relationship to stroke and dementia J Alzheimers Dis 3 65 73 1:CAS:528:DC%2BD3MXjs1eju7c%3D 12214074 (Pubitemid 32238252)
9. K. Iqbal I. Grundke-Iqbal 2006 Discoveries of tau, abnormally hyperphosphorylated tau and others of neurofibrillary degeneration: a personal historical perspective J Alzheimers Dis. 9 219 242 1:CAS:528: DC%2BD28XotFKktL4%3D 16914861 (Pubitemid 44253315)
10. K. Iqbal I. Grundke-Iqbal 2008 Alzheimer neurofibrillary degeneration: significance, etiopathogenesis, therapeutics and prevention J Cell Mol Med 12 38 55 1:CAS:528:DC%2BD1cXltlSru7Y%3D 18194444 10.1111/j.1582-4934.2008.00225.x (Pubitemid 351436349)
11. K. Iqbal I. Grundke-Iqbal 2005 Pharmacological approaches of neurofibrillary degeneration Curr Alzheimer Res 2 335 341 1:CAS:528: DC%2BD2MXmtFKqurk%3D 15974899 10.2174/1567205054367810 (Pubitemid 40980192)
12. W.H. Zheng S. Bastianetto F. Mennicken, et al. 2002 Amyloid beta peptide induces tau phosphorylation and loss of cholinergic neurons in rat primary septal cultures Neuroscience 115 201 211 1:CAS:528:DC%2BD38XotVWhtb0%3D 12401334 10.1016/S0306-4522(02)00404-9 (Pubitemid 35232701)
13. P.V. Arriagada J.H. Growdon E.T. Hedley-Whyte, et al. 1992 Neurofibrillary tangles but not senile plaques parallel duration and severity of Alzheimer's disease Neurology 42 631 639 1:STN:280:DyaK387psFCktw%3D%3D 1549228
14. K. Blennow 2004 Cerebrospinal fluid protein biomarkers for Alzheimer's disease NeuroRx 1 213 225 15717022 10.1602/neurorx.1.2.213 (Pubitemid 46589353)
15. D.J. Selkoe D. Schenk 2003 Alzheimer's disease: molecular understanding predicts amyloid-based therapeutics Annu Rev Pharmacol Toxicol 43 545 584 1:CAS:528:DC%2BD3sXitFWqt74%3D 12415125 10.1146/annurev.pharmtox.43.100901. 140248 (Pubitemid 37372653)
16. D. Schenk R. Barbour W. Dunn, et al. 1999 Immunization with amyloid-Beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse Nature 400 173 177 1:CAS:528:DyaK1MXks1Khsbc%3D 10408445 10.1038/22124 (Pubitemid 29327547)
17. D. Morgan D.M. Diamond P.E. Gottschall, et al. 2000 A beta peptide vaccination prevents memory loss in an animal model of Alzheimer's disease Nature 408 982 985 1:CAS:528:DC%2BD3MXhslWrsQ%3D%3D 11140686 10.1038/35050116 (Pubitemid 32101645)
18. V. Lavie M. Becker R. Cohen-Kupiec, et al. 2004 EFRH-phage immunization of Alzheimer's disease animal model improves behavioral performance in Morris water maze trials J Mol Neurosci 24 105 113 1:CAS:528:DC%2BD2cXnsFWksbw%3D 15314258 10.1385/JMN:24:1:105 (Pubitemid 41359175)
19. J.M. Orgogozo S. Gilman J.F. Dartigues, et al. 2003 Subacute meningoencephalitis in a subset of patients with AD after ABeta42 immunization Neurology 61 46 54 1:CAS:528:DC%2BD3sXks1OktLk%3D 12847155 (Pubitemid 36818745)
20. C. Hock U. Konietzko J.R. Streffer, et al. 2003 Antibodies against Beta-amyloid slow cognitive decline in Alzheimer's disease Neuron 38 547 554 1:CAS:528:DC%2BD3sXksVOjs7c%3D 12765607 10.1016/S0896-6273(03)00294-0 (Pubitemid 36645030)
21. S. Gilman M. Koller R.S. Black, et al. 2005 Clinical effects of ABeta immunization (AN1792) in patients with AD in an interrupted trial Neurology 64 1553 1562 1:CAS:528:DC%2BD2MXjsVCjsbg%3D 15883316 10.1212/01.WNL.0000159740. 16984.3C (Pubitemid 40617691)
22. A. Woodhouse T.C. Dickson J.C. Vickers 2007 Vaccination strategies for Alzheimer's disease: A new hope? Drugs Aging 24 107 119 1:CAS:528: DC%2BD2sXkvVOgsLk%3D 17313199 10.2165/00002512-200724020-00003 (Pubitemid 46327570)
23. M. Pride P. Seubert M. Grundman, et al. 2008 Progress in the active immunotherapeutic approach to Alzheimer's disease: clinical investigations into AN1792-associated meningoencephalitis Neurodegener Dis 5 194 196 1:CAS:528:DC%2BD1cXjs1WhtLo%3D 18322388 10.1159/000113700 (Pubitemid 351347848)
24. F. Bard C. Cannon R. Barbour, et al. 2000 Peripherally administered antibodies against amyloid Beta-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease Nat Med 6 916 919 1:CAS:528:DC%2BD3cXlsFamtL4%3D 10932230 10.1038/78682 (Pubitemid 30644751)
25. R.B. DeMattos K.R. Bales D.J. Cummins, et al. 2001 Peripheral anti-A Beta antibody alters CNS and plasma A Beta clearance and decreases brain A Beta burden in a mouse model of Alzheimer's disease Proc Natl Acad Sci USA 98 8850 8855 1:CAS:528:DC%2BD3MXls1Wiurk%3D 11438712 10.1073/pnas.151261398 (Pubitemid 32678116)
26. F. Goni E.M. Sigurdsson 2005 New directions towards safer and effective vaccines for Alzheimer's disease Curr Opin Mol Ther 7 17 23 1:CAS:528: DC%2BD2MXit1Cqt7Y%3D 15732525 (Pubitemid 40287451)
27. M.M. Racke L.I. Boone D.L. Hepburn, et al. 2005 Exacerbation of cerebral amyloid angiopathy associated microhemorrhage in amyloid precursor protein transgenic mice by immunotherapy is dependent on antibody recognition of deposited forms of amyloid Beta J Neurosci 25 629 636 1:CAS:528: DC%2BD2MXhtFOktL8%3D 15659599 10.1523/JNEUROSCI.4337-04.2005
28. I. Rakover M. Arbel B. Solomon 2007 Immunotherapy against APP beta-secretase cleavage site improves cognitive function and reduces neuroinflammation in Tg2576 mice without a significant effect on brain abeta levels Neurodegener Dis 4 392 402 1:CAS:528:DC%2BD2sXotVOjtr4%3D 17536186 10.1159/000103250 (Pubitemid 47123466)
29. R.C. Dodel Y. Du C. Depboylu, et al. 2004 Intravenous immunoglobulins containing antibodies against Beta-amyloid for the treatment of Alzheimer's disease J Neurol Neurosurg Psychiatry 75 1472 1474 1:STN:280: DC%2BD2cvpvFyqsA%3D%3D 15377700 10.1136/jnnp.2003.033399 (Pubitemid 39279821)
30. S.F. Lichtenthaler C. Haass 2004 Amyloid at the cutting edge: activation of alpha-secretase prevents amyloidogenesis in an Alzheimer disease mouse model J Clin Invest 113 1384 1387 1:CAS:528:DC%2BD2cXktlCltr4%3D 15146234 (Pubitemid 39071692)
31. Y. Luo B. Bolon S. Kahn, et al. 2001 Mice deficient in BACE1, the Alzheimer's Betasecretase, have normal phenotype and abolished Beta-amyloid generation Nat Neurosci 4 231 232 1:CAS:528:DC%2BD3MXhsF2rtbY%3D 11224535 10.1038/85059 (Pubitemid 32194866)
32. I. Hussain J. Hawkins D. Harrison, et al. 2007 Oral administration of a potent and selective non-peptidic BACE-1 inhibitor decreases beta-cleavage of amyloid precursor protein and amyloid-beta production in vivo J Neurochem 100 802 809 1:CAS:528:DC%2BD2sXhvFGgt7Y%3D 17156133 10.1111/j.1471-4159.2006.04260.x (Pubitemid 46095629)
33. L. Rajendran A. Schneider G. Schlechtingen, et al. 2008 Efficient inhibition of the Alzheimer's disease beta-secretase by membrane targeting Science 320 520 523 1:CAS:528:DC%2BD1cXkvFGkt74%3D 18436784 10.1126/science. 1156609 (Pubitemid 351590663)
34. T.A. Comery R.L. Martone S. Aschmies, et al. 2005 Acute gamma-secretase inhibition improves contextual fear conditioning in the Tg2576 mouse model of Alzheimer's disease J Neurosci 25 8898 8902 1:CAS:528:DC%2BD2MXhtVOqs7rE 16192379 10.1523/JNEUROSCI.2693-05.2005 (Pubitemid 41384457)
35. H.F. Dovey V. John J.P. Anderson, et al. 2001 Functional gamma-secretase inhibitors reduce beta-amyloid peptide levels in brain J Neurochem 76 173 181 1:CAS:528:DC%2BD3MXhtVGlsb4%3D 11145990 10.1046/j.1471-4159.2001.00012.x (Pubitemid 32044380)
36. D. Hartmann J. Tournoy P. Saftig, et al. 2001 Implication of APP secretases in notch signaling J Mol Neurosci 17 171 181 1:CAS:528: DC%2BD3MXosVKit7w%3D 11816790 10.1385/JMN:17:2:171 (Pubitemid 33063521)
37. D.M. Barten J.E. Meredith Jr R. Zaczek, et al. 2006 Gamma-secretase inhibitors for Alzheimer's disease: balancing efficacy and toxicity Drugs R D 7 87 97 1:CAS:528:DC%2BD28XltVWksrg%3D 16542055 10.2165/00126839-200607020-00003
38. G.T. Wong D. Manfra F.M. Poulet, et al. 2004 Chronic treatment with the gamma-secretase inhibitor LY-411,575 inhibits beta-amyloid peptide production and alters lymphopoiesis and intestinal cell differentiation J Biol Chem 279 12876 12882 1:CAS:528:DC%2BD2cXitl2gtb0%3D 14709552 10.1074/jbc.M311652200 (Pubitemid 38445862)
39. E. Siemers M. Skinner R.A. Dean, et al. 2005 Safety, tolerability, and changes in amyloid beta concentrations after administration of a gamma-secretase inhibitor in volunteers Clin Neuropharmacol 28 126 132 1:CAS:528: DC%2BD2MXltlSrurw%3D 15965311 10.1097/01.wnf.0000167360.27670.29 (Pubitemid 40923411)
40. E.R. Siemers R.A. Dean S. Friedrich, et al. 2007 Safety, Tolerability, and Effects on Plasma and Cerebrospinal Fluid Amyloid-beta After Inhibition of gamma-Secretase Clin Neuropharmacol 30 317 325 1:CAS:528:DC%2BD1cXjsVahug%3D%3D 18090456 10.1097/WNF.0b013e31805b7660 (Pubitemid 350307310)
41. E.R. Siemers J.F. Quinn J. Kaye, et al. 2006 Effects of a gamma-secretase inhibitor in a randomized study of patients with Alzheimer disease Neurology 66 602 604 1:CAS:528:DC%2BD28XhtFeis7s%3D 16505324 10.1212/01.WNL.0000198762. 41312.E1 (Pubitemid 43739900)
42. G. Frick S. Raje H. Wan, et al. 2008 P4-366: GSI-953, a potent and selective gammasecretase inhibitor: Modulation of beta-amyloid peptides and plasma and cerebrospinal fluid pharmacokinetic/pharmacodynamic relationships in humans Alzheimer's and Dementia 4 T781 10.1016/j.jalz.2008.05.2437
43. M.K. Sun D.L. Alkon 2005 Protein kinase C isozymes: memory therapeutic potential Curr Drug Targets CNS Neurol Disord 4 541 552 1:CAS:528: DC%2BD2MXhtV2gsLrM 16266287 10.2174/156800705774322120 (Pubitemid 41448380)
44. R. Etcheberrigaray M. Tan I. Dewachter, et al. 2004 Therapeutic effects of PKC activators in Alzheimer's disease transgenic mice Proc Natl Acad Sci U S A 101 11141 11146 1:CAS:528:DC%2BD2cXmsVCmtbo%3D 15263077 10.1073/pnas. 0403921101 (Pubitemid 38989597)
45. G.K. Wilcock S.E. Black S.B. Hendrix, et al. 2008 Efficacy and safety of tarenflurbil in mild to moderate Alzheimer's disease: a randomised phase II trial Lancet Neurol 7 483 493 1:CAS:528:DC%2BD1cXntlSjtL8%3D 18450517 10.1016/S1474-4422(08)70090-5
46. N.N. Nalivaeva L.R. Fisk N.D. Belyaev, et al. 2008 Amyloid-degrading enzymes as therapeutic targets in Alzheimer's disease Curr Alzheimer Res 5 212 224 1:CAS:528:DC%2BD1cXkt1alsL0%3D 18393806 10.2174/156720508783954785 (Pubitemid 351536346)
47. M.A. Leissring W. Farris A.Y. Chang, et al. 2003 Enhanced proteolysis of Beta-amyloid in APP transgenic mice prevents plaque formation, secondary pathology, and premature death Neuron 40 1087 1093 1:CAS:528: DC%2BD2cXhtVGrtQ%3D%3D 14687544 10.1016/S0896-6273(03)00787-6 (Pubitemid 38032786)
48. K. Yasojima E.G. McGeer P.L. McGeer 2001 Relationship between beta amyloid peptide generating molecules and neprilysin in Alzheimer disease and normal brain Brain Res 919 115 121 1:CAS:528:DC%2BD3MXnvFCksbc%3D 11689168 10.1016/S0006-8993(01)03008-6 (Pubitemid 33016594)
49. R.A. Marr E. Rockenstein A. Mukherjee, et al. 2003 Neprilysin gene transfer reduces human amyloid pathology in transgenic mice J Neurosci 23 1992 1996 1:CAS:528:DC%2BD3sXlsV2qs7c%3D 12657655 (Pubitemid 36368884)
50. T. Saito N. Iwata S. Tsubuki, et al. 2005 Somatostatin regulates brain amyloid Beta peptide ABeta42 through modulation of proteolytic degradation Nat Med 11 434 439 1:CAS:528:DC%2BD2MXivFCgsrs%3D 15778722 10.1038/nm1206 (Pubitemid 40562335)
51. N. Iwata M. Higuchi T.C. Saido 2005 Metabolism of amyloid-beta peptide and Alzheimer's disease Pharmacol Ther 108 129 148 1:CAS:528:DC%2BD2MXhtFKhsrrO 16112736 10.1016/j.pharmthera.2005.03.010 (Pubitemid 41527082)
52. K. Tokita T. Inoue S. Yamazaki, et al. 2005 FK962, a novel enhancer of somatostatin release, exerts cognitive-enhancing actions in rats Eur J Pharmacol 527 111 120 1:CAS:528:DC%2BD2MXht1Olur7N 16325809 10.1016/j.ejphar.2005.10.022 (Pubitemid 41745158)
53. J.S. Jacobsen T.A. Comery R.L. Martone, et al. 2008 Enhanced clearance of Abeta in brain by sustaining the plasmin proteolysis cascade Proc Natl Acad Sci U S A 105 8754 8759 1:CAS:528:DC%2BD1cXot1emtr0%3D 18559859 10.1073/pnas.0710823105 (Pubitemid 351987752)
54. P.S. Aisen 2005 The development of anti-amyloid therapy for Alzheimer's disease: from secretase modulators to polymerisation inhibitors CNS Drugs 19 989 996 1:CAS:528:DC%2BD28Xnt12qsw%3D%3D 16332141 10.2165/00023210-200519120-00002 (Pubitemid 41775990)
55. F. Gervais J. Paquette C. Morissette, et al. 2007 Targeting soluble Abeta peptide with Tramiprosate for the treatment of brain amyloidosis Neurobiol Aging 28 537 547 1:CAS:528:DC%2BD2sXitFyks74%3D 16675063 10.1016/j. neurobiolaging.2006.02.015 (Pubitemid 46282205)
56. P.S. Aisen D. Saumier R. Briand, et al. 2006 A Phase II study targeting amyloid-beta with 3APS in mild-to-moderate Alzheimer disease Neurology 67 1757 1763 1:CAS:528:DC%2BD28Xht1SjsLzN 17082468 10.1212/01.wnl.0000244346.08950.64 (Pubitemid 44900749)
57. T.M. Wright 2006 Tramiprosate Drugs Today (Barc) 42 291 298 1:CAS:528:DC%2BD28XntVWhsrY%3D 10.1358/dot.2006.42.5.973584 (Pubitemid 43980714)
58. A.E. Finefrock A.I. Bush P.M. Doraiswamy 2003 Current status of metals as therapeutic targets in Alzheimer's disease J Am Geriatr Soc 51 1143 1148 12890080 10.1046/j.1532-5415.2003.51368.x (Pubitemid 36993474)
59. M.P. Cuajungco C.J. Frederickson A.I. Bush 2005 Amyloid-beta metal interaction and metal chelation Subcell Biochem 38 235 254 1:CAS:528: DC%2BD2MXotFaktrk%3D 15709482 10.1007/0-387-23226-5-12
60. A. Dedeoglu K. Cormier S. Payton, et al. 2004 Preliminary studies of a novel bifunctional metal chelator targeting Alzheimer's amyloidogenesis Exp Gerontol 39 1641 1649 1:CAS:528:DC%2BD2cXhtVCltLbJ 15582280 10.1016/j.exger. 2004.08.016 (Pubitemid 39585199)
61. J.Y. Lee J.E. Friedman I. Angel, et al. 2004 The lipophilic metal chelator DP-109 reduces amyloid pathology in brains of human beta-amyloid precursor protein transgenic mice Neurobiol Aging 25 1315 1321 1:CAS:528:DC%2BD2cXotFCmu78%3D 15465629 10.1016/j.neurobiolaging.2004.01.005 (Pubitemid 39299169)
62. C.W. Ritchie A.I. Bush A. Mackinnon, et al. 2003 Metal-protein attenuation with iodochlorhydroxyquin (clioquinol) targeting Abeta amyloid deposition and toxicity in Alzheimer disease: a pilot phase 2 clinical trial Arch Neurol 60 1685 1691 14676042 10.1001/archneur.60.12.1685 (Pubitemid 37521621)
63. Sampson E, Jenagaratnam L, McShane R. Metal protein attenuating compounds for the treatment of Alzheimer's disease. Cochrane Database Syst Rev 2008;1:CD005380.
64. G. Liu M.R. Garrett P. Men, et al. 2005 Nanoparticle and other metal chelation therapeutics in Alzheimer disease Biochim Biophys Acta 1741 246 252 1:CAS:528:DC%2BD2MXhtVegurvL 16051470 (Pubitemid 41338670)
65. L. Lannfelt K. Blennow H. Zetterberg, et al. 2008 Safety, efficacy, and biomarker findings of PBT2 in targeting Abeta as a modifying therapy for Alzheimer's disease: a phase IIa, double-blind, randomised, placebo-controlled trial Lancet Neurol 7 779 786 1:CAS:528:DC%2BD1cXhtFWmsL3F 18672400 10.1016/S1474-4422(08)70167-4
66. H. Jick G.L. Zornberg S.S. Jick, et al. 2000 Statins and the risk of dementia Lancet 356 1627 1631 1:CAS:528:DC%2BD3cXotlCnsrc%3D 11089820 10.1016/S0140-6736(00)03155-X
67. L. Canevari J.B. Clark 2007 Alzheimer's disease and cholesterol: the fat connection Neurochem Res 32 739 750 1:CAS:528:DC%2BD2sXjtlymsbw%3D 17191138 10.1007/s11064-006-9200-1 (Pubitemid 46481303)
68. J.M. Cordy N.M. Hooper A.J. Turner 2006 The involvement of lipid rafts in Alzheimer's disease Mol Membr Biol 23 111 122 1:CAS:528:DC%2BD28Xis1Citb8%3D 16611586 10.1080/09687860500496417
69. D.L. Sparks M.N. Sabbagh D.J. Connor, et al. 2005 Atorvastatin for the treatment of mild to moderate Alzheimer disease: preliminary results Arch Neurol 62 753 757 15883262 10.1001/archneur.62.5.753 (Pubitemid 40656090)
70. M. Simons F. Schwärzler D. Lütjohann, et al. 2002 Treatment with simvastatin in normocholesterolemic patients with Alzheimer's disease: A 26-week randomized, placebo-controlled, double-blind trial Ann Neurol 52 346 350 1:CAS:528:DC%2BD38Xns1amtr4%3D 12205648 10.1002/ana.10292 (Pubitemid 35001502)
71. R.W. Jones M. Kivipelto H. Feldman, et al. 2008 The Atorvastatin/ Donepezil in Alzheimer's Disease Study (LEADe): design and baseline characteristics Alzheimers Dement 4 145 153 1:CAS:528:DC%2BD1cXltlSmtbk%3D 18631958 10.1016/j.jalz.2008.02.001 (Pubitemid 351373204)
72. G. Stuchbury G. Münch 2005 Alzheimer's associated inflammation, potential drug targets and future therapies J Neural Transm 112 429 453 1:STN:280:DC%2BD2M%2Fpt1eitg%3D%3D 15723159 10.1007/s00702-004-0188-x (Pubitemid 40868053)
73. L.F. Lue D.G. Walker L. Brachova, et al. 2001 Involvement of microglial receptor for advanced glycation endproducts (RAGE) in Alzheimer's disease: identification of a cellular activation mechanism Exp Neurol 171 29 45 1:CAS:528:DC%2BD3MXmtFyqtrc%3D 11520119 10.1006/exnr.2001.7732 (Pubitemid 32848443)
74. I.G. Onyango J.B. Tuttle J.P. Bennett Jr. 2005 Altered intracellular signaling and reduced viability of Alzheimer's disease neuronal cybrids is reproduced by beta-amyloid peptide acting through receptor for advanced glycation end products (RAGE) Mol Cell Neurosci 29 333 343 1:CAS:528: DC%2BD2MXks1Wlu70%3D 15911356 10.1016/j.mcn.2005.02.012 (Pubitemid 40725622)
75. A. Maczurek K. Shanmugam G. Münch 2008 Inflammation and the redox-sensitive AGERAGE pathway as a therapeutic target in Alzheimer's disease Ann N Y Acad Sci 1126 147 151 1:CAS:528:DC%2BD1cXmtFygu74%3D 18448809 10.1196/annals.1433.026 (Pubitemid 351589288)
76. G. Drewes 2004 MARKing tau for tangles and toxicity Trends Biochem Sci 29 548 555 1:CAS:528:DC%2BD2cXnvVOhs7s%3D 15450610 10.1016/j.tibs.2004.08.001 (Pubitemid 39265172)
77. L. Munoz H.R. Ranaivo S.M. Roy, et al. 2007 A novel p38 alpha MAPK inhibitor suppresses brain proinflammatory cytokine up-regulation and attenuates synaptic dysfunction and behavioral deficits in an Alzheimer's disease mouse model J Neuroinflammation 4 21 17784957 10.1186/1742-2094-4-21 1:CAS:528:DC%2BD2sXhtlajtLbE (Pubitemid 47570621)
78. C.J. Phiel C.A. Wilson V.M. Lee, et al. 2003 GSK-3alpha regulates production of Alzheimer's disease amyloid-beta peptides Nature 423 435 439 1:CAS:528:DC%2BD3sXjvFaltLY%3D 12761548 10.1038/nature01640 (Pubitemid 36626994)
79. H.C. Huang P.S. Klein 2006 Multiple roles for glycogen synthase kinase-3 as a drug target in Alzheimer's disease Curr Drug Targets. 7 11 1389 1397 1:CAS:528:DC%2BD28XhtFensL%2FE 17100579 (Pubitemid 44718299)
80. W.Q. Zhao C. Feng D.L. Alkon 2003 Impairment of phosphatase 2A contributes to the prolonged MAP kinase phosphorylation in Alzheimer's disease fibroblasts Neurobiol Dis 14 458 469 1:CAS:528:DC%2BD3sXpvVWksbw%3D 14678762 10.1016/S0969-9961(03)00124-4 (Pubitemid 37543524)
81. H. Tanimukai I. Grundke-Iqbal K. Iqbal 2005 Up-regulation of inhibitors of protein phosphatase-2A in Alzheimer's disease Am J Pathol 166 1761 1771 1:CAS:528:DC%2BD2MXlsFynsrc%3D 15920161 10.1016/S0002-9440(10)62486-8 (Pubitemid 40734399)
82. J.Z. Wang I. Grundke-Iqbal K. Iqbal 2007 Kinases and phosphatases and tau sites involved in Alzheimer neurofibrillary degeneration Eur J Neurosci 25 59 68 17241267 10.1111/j.1460-9568.2006.05226.x (Pubitemid 46098893)
83. Q. Wei M. Holzer M.K. Brueckner, et al. 2002 Dephosphorylation of tau protein by calcineurin triturated into neural living cells Cell Mol Neurobiol 22 13 24 1:CAS:528:DC%2BD38XltFagtb4%3D 12064514 10.1023/A:1015385527187 (Pubitemid 34579405)
84. Q. Lian C.J. Ladner D. Magnuson, et al. 2001 Selective changes of calcineurin (protein phosphatase 2B) activity in Alzheimer's disease cerebral cortex Exp Neurol 167 158 165 1:CAS:528:DC%2BD3MXls1Wntg%3D%3D 11161603 10.1006/exnr.2000.7534 (Pubitemid 32066418)
85. M. Hong D.C. Chen P.S. Klein, et al. 1997 Lithium reduces tau phosphorylation by inhibition of glycogen synthase kinase-3 J Biol Chem 272 25326 25332 1:CAS:528:DyaK2sXms1eht70%3D 9312151 10.1074/jbc.272.40.25326 (Pubitemid 27415724)
86. A. Rametti F. Esclaire C. Yardin, et al. 2008 Lithium down-regulates tau in cultured cortical neurons: a possible mechanism of neuroprotection Neurosci Lett 434 93 98 1:CAS:528:DC%2BD1cXjtlygsL0%3D 18289787 10.1016/j.neulet.2008.01. 034
87. A. Gómez-Ramos J. Domínguez D. Zafra, et al. 2006 Inhibition of GSK3 dependent tau phosphorylation by metals Curr Alzheimer Res 3 123 127 16611012 10.2174/156720506776383059
88. E. Rockenstein M. Torrance A. Adame, et al. 2007 Neuroprotective effects of regulators of the glycogen synthase kinase-3beta signaling pathway in a transgenic model of Alzheimer's disease are associated with reduced amyloid precursor protein phosphorylation J Neurosci 27 1981 1991 1:CAS:528: DC%2BD2sXivV2jur8%3D 17314294 10.1523/JNEUROSCI.4321-06.2007
89. A. Caccamo S. Oddo L.X. Tran, et al. 2007 Lithium reduces tau phosphorylation but not A beta or working memory deficits in a transgenic model with both plaques and tangles Am J Pathol 170 1669 1675 1:CAS:528: DC%2BD2sXlvFCnsb4%3D 17456772 10.2353/ajpath.2007.061178 (Pubitemid 47339311)
90. H. Hampel M. Ewers K. Bürger, et al. 2008 Lithium trial in Alzheimer's disease: A randomized, single-blinded, placebo-controlled, parallel group multicentre 10-week study Alzheimer's & Dementia: The Journal of the Alzheimer's Association 4 T782
91. Deiana S, Harrington CR, Wischik CM, et al. Methylthioninium chloride reverses cognitive deficits induced by scopolamine: comparison with rivastigmine. Psychopharmacology (Berl) 2008; epub ahead of print.
92. A. Nunomura R.J. Castellani X. Zhu, et al. 2006 Involvement of oxidative stress in Alzheimer disease J Neuropathol Exp Neurol 65 631 641 1:CAS:528:DC%2BD28XotFeiu7o%3D 16825950 10.1097/01.jnen.0000228136.58062.bf (Pubitemid 44297254)
93. W.R. Markesbery J.M. Carney 1999 Oxidative alterations in Alzheimer's disease Brain Pathol 9 133 146 1:CAS:528:DyaK1MXht1Cmsbw%3D 9989456 10.1111/j.1750-3639.1999.tb00215.x (Pubitemid 29056524)
94. J.N. Keller F.A. Schmitt S.W. Scheff, et al. 2005 Evidence of increased oxidative damage in subjects with mild cognitive impairment Neurology 64 1152 1156 1:CAS:528:DC%2BD2MXislSmu7k%3D 15824339
95. A. Nunomura G. Perry G. Aliev, et al. 2001 Oxidative damage is the earliest event in Alzheimer disease J Neuropathol Exp Neurol 60 759 767 1:CAS:528:DC%2BD3MXmtVGmsr0%3D 11487050 (Pubitemid 32678256)
96. D. Praticò K. Uryu S. Leight, et al. 2001 Increased lipid peroxidation precedes amyloid plaque formation in an animal model of Alzheimer amyloidosis J Neurosci 21 4183 4187 11404403 (Pubitemid 32538543)
97. M.J. Engelhart M.I. Geerlings A. Ruitenberg, et al. 2002 Dietary intake of antioxidants and risk of Alzheimer disease JAMA 287 3223 3229 1:CAS:528:DC%2BD38XkvVOjtrw%3D 12076218 10.1001/jama.287.24.3223 (Pubitemid 34686103)
98. J.M. Lewis 1992 Vitamin A and Alzheimer's disease Neuroepidemiology 11 163 168 1:STN:280:DyaK3s%2FisFamtg%3D%3D 1407253 10.1159/000110927
99. P.P. Zandi J.C. Anthony A.S. Khachaturian, et al. 2004 Reduced risk of Alzheimer disease in users of antioxidant vitamin supplements: the Cache County Study Arch Neurol 61 82 88 14732624 10.1001/archneur.61.1.82 (Pubitemid 38067418)
100. K.H. Masaki K.G. Losonczy G. Izmirlian, et al. 2000 Association of vitamin E and C supplement use with cognitive function and dementia in elderly men Neurology 54 1265 1272 1:CAS:528:DC%2BD3cXisFOnsL0%3D 10746596 (Pubitemid 30174045)
101. D. Laurin K.H. Masaki D.J. Foley, et al. 2004 Midlife dietary intake of antioxidants and risk of late-life incident dementia: the Honolulu-Asia Aging Study Am J Epidemiol 159 959 967 15128608 10.1093/aje/kwh124 (Pubitemid 38608273)
102. T.L. Wadsworth J.A. Bishop A.S. Pappu, et al. 2008 Evaluation of coenzyme Q as an antioxidant strategy for Alzheimer's disease J Alzheimers Dis 14 225 234 1:CAS:528:DC%2BD1cXmvFGltro%3D 18560133 (Pubitemid 352040040)
103. A.J. Young S. Johnson D.C. Steffens, et al. 2007 Coenzyme Q10: a review of its promise as a neuroprotectant CNS Spectr 12 62 68 17192765 (Pubitemid 46155305)
104. S. Kalmijn M.P. van Boxtel M. Ocké, et al. 2004 Dietary intake of fatty acids and fish in relation to cognitive performance at middle age Neurology 62 275 280 1:CAS:528:DC%2BD2cXhtV2quw%3D%3D 14745067 (Pubitemid 38167138)
105. M.C. Morris D.A. Evans J.L. Bienias, et al. 2003 Consumption of fish and n-3 fatty acids and risk of incident Alzheimer disease Arch Neurol 60 940 946 12873849 10.1001/archneur.60.7.940 (Pubitemid 36858352)
106. M. Sano C. Ernesto R.G. Thomas, et al. 1997 A controlled trial of selegiline, alpha-tocopherol, or both as treatment for Alzheimer's disease N Engl J Med 336 1216 1222 1:CAS:528:DyaK2sXivFylsrs%3D 9110909 10.1056/NEJM199704243361704 (Pubitemid 27183651)
107. E.R. Miller 3rd R. Pastor-Barruiuso D. Dalal, et al. 2005 Meta analysis: High dosage vitamin E supplementation may increase all-cause mortality Ann Intern Med 142 37 46 1:CAS:528:DC%2BD2MXjvFyqtbY%3D 15537682
108. E. Lonn J. Bosch S. Yusuf, et al. 2005 Effects of long-term vitamin E supplementation on cardiovascular events and cancer: A randomized controlled trial JAMA 293 1338 1347 15769967 10.1001/jama.293.11.1338 (Pubitemid 40381486)
109. Isaac M, Quinn R, Tabet N. Vitamin E for Alzheimer's disease and mild cognitive impairment. Cochrane Database of Systematic Reviews 2000;4:CD002854.
110. D.H. Lee A.R. Folsom L. Harnack, et al. 2004 Does supplemental vitamin C increase cardiovascular disease risk in women with diabetes? Am J Clin Nutr 80 1194 1200 1:CAS:528:DC%2BD2cXhtVSnt7rM 15531665 (Pubitemid 41350678)
111. L.A. Boothby P.L. Doering 2005 Vitamin C and vitamin E for Alzheimer's disease Ann Pharmacother 39 2073 2080 1:CAS:528:DC%2BD28Xkt1Cquw%3D%3D 16227450 10.1345/aph.1E495 (Pubitemid 41745953)
112. P. Barberger-Gateau C. Raffaitin L. Letenneur, et al. 2007 Dietary patterns and risk of dementia: the Three-City cohort study Neurology 69 1921 1930 1:STN:280:DC%2BD2snntleitg%3D%3D 17998483 10.1212/01.wnl.0000278116.37320. 52 (Pubitemid 350100350)
113. S.K. Orr R.P. Bazinet 2008 The emerging role of docosahexaenoic acid in neuroinflammation Curr Opin Investig Drugs 9 735 743 1:CAS:528: DC%2BD1cXpt1ajtLc%3D 18600579 (Pubitemid 351950870)
114. Y. Freund-Levi M. Eriksdotter-Jönhagen T. Cederholm, et al. 2006 Omega-3 fatty acid treatment in 174 patients with mild to moderate Alzheimer disease: OmegAD study: a randomized double-blind trial Arch Neurol 63 1402 1408 17030655 10.1001/archneur.63.10.1402 (Pubitemid 44547551)
115. L. Holmquist G. Stuchbury K. Berbaum, et al. 2007 Lipoic acid as a novel treatment for Alzheimer's disease and related dementias Pharmacol Ther 113 154 164 1:CAS:528:DC%2BD2sXhsFCkug%3D%3D 16989905 10.1016/j.pharmthera.2006.07.001 (Pubitemid 44969927)
116. M.A. Lovell C. Xie S. Xiong, et al. 2003 Protection against amyloid beta peptide and iron/hydrogen peroxide toxicity by alpha lipoic acid J Alzheimers Dis. 5 229 239 1:CAS:528:DC%2BD3sXlsl2rtbY%3D 12897407 (Pubitemid 37279553)
117. P.I. Moreira P.L. Harris X. Zhu, et al. 2007 Lipoic acid and N-acetyl cysteine decrease mitochondrial-related oxidative stress in Alzheimer disease patient fibroblasts J Alzheimers Dis 12 195 206 1:CAS:528:DC%2BD2sXhtV2isrnL 17917164 (Pubitemid 47509369)
118. A. Maczurek K. Hager M. Kenklies, et al. 2008 Lipoic acid as an anti-inflammatory and neuroprotective treatment for Alzheimer's disease Adv Drug Deliv Rev 60 1463 1470 1:CAS:528:DC%2BD1cXhtFWltbnF 18655815 10.1016/j.addr.2008.04.015
119. K. Hager M. Kenklies J. McAfoose, et al. 2007 Alpha-lipoic acid as a new treatment option for Alzheimer's disease - a 48 months follow-up analysis J Neural Transm Suppl 72 189 193 1:CAS:528:DC%2BD2sXhsVKns7nL 17982894 10.1007/978-3-211-73574-9-24
120. C. Ramassamy F. Longpré Y. Christen 2007 Ginkgo biloba extract (EGb 761) in Alzheimer's disease: is there any evidence? Curr Alzheimer Res 4 253 262 1:CAS:528:DC%2BD2sXntlCqtLg%3D 17627482 10.2174/156720507781077304 (Pubitemid 47025423)
121. Y. Luo J.V. Smith V. Paramasivam, et al. 2002 Inhibition of amyloid-beta aggregation and caspase-3 activation by the Ginkgo biloba extract EGb761 Proc Natl Acad Sci U S A 99 12197 12202 1:CAS:528:DC%2BD38XntlCksro%3D 12213959 10.1073/pnas.182425199
122. S. Andrieu S. Gillette K. Amouyal F. Nourhashemi, et al. 2003 Association of Alzheimer's disease onset with ginkgo biloba and other symptomatic cognitive treatments in a population of women aged 75 years and older from the EPIDOS study J Gerontol A Biol Sci Med Sci 58 372 377 12663701 (Pubitemid 36397055)
123. L.S. Schneider S.T. DeKosky M.R. Farlow, et al. 2005 A randomized, double-blind, placebocontrolled trial of two doses of Ginkgo biloba extract in dementia of the Alzheimer's type Curr Alzheimer Res 2 541 551 1:CAS:528:DC%2BD2MXht1CgtLrN 16375657 10.2174/156720505774932287 (Pubitemid 41703672)
124. M. Van Dongen E. van Rossum A. Kessels, et al. 2003 Ginkgo for elderly people with dementia and age-associated memory impairment: a randomized clinical trial J Clin Epidemiol 56 367 376 12767414 10.1016/S0895-4356(03)00003-9 (Pubitemid 36593316)
125. M.C. Van Dongen E. van Rossum A.G. Kessels, et al. 2000 The efficacy of ginkgo for elderly people with dementia and age-associated memory impairment: new results of a randomized clinical trial J Am Geriatr Soc 48 1183 1194 11037003
126. S. Kanowski R. Hoerr 2003 Ginkgo biloba extract EGb 761 in dementia: intent-to-treat analyses of a 24-week, multi-center, double-blind, placebo-controlled, randomized trial Pharmacopsychiatry 36 297 303 1:CAS:528:DC%2BD2cXhtVSiuro%3D 14663654 10.1055/s-2003-45117 (Pubitemid 38085148)
127. P.L. Le Bars M. Kieser K.Z. Itil 2000 A 26-week analysis of a double-blind, placebocontrolled trial of the ginkgo biloba extract EGb 761 in dementia Dement Geriatr Cogn Disord 11 230 237 10867450 10.1159/000017242 (Pubitemid 30416029)
128. A. Kurz B. Van Baelen 2004 Ginkgo biloba compared with cholinesterase inhibitors in the treatment of dementia: a review based on meta-analyses by the cochrane collaboration Dement Geriatr Cogn Disord 18 217 226 1:STN:280:DC%2BD2cvgtV2ruw%3D%3D 15237280 10.1159/000079388 (Pubitemid 39140373)
129. M. Mazza A. Capuano P. Bria, et al. 2006 Ginkgo biloba and donepezil: a comparison in the treatment of Alzheimer's dementia in a randomized placebo-controlled doubleblind study Eur J Neurol 13 981 985 1:STN:280:DC%2BD28rgs1Ohsw%3D%3D 16930364 10.1111/j.1468-1331.2006.01409.x (Pubitemid 44284905)
130. J.S. Tauskela 2007 MitoQ - a mitochondria-targeted antioxidant IDrugs 10 399 412 1:CAS:528:DC%2BD2sXotFyks78%3D 17642004
131. S. Wang L. Zhu H. Shi, et al. 2007 Inhibition of melatonin biosynthesis induces neurofilament hyperphosphorylation with activation of cyclin-dependent kinase 5 Neurochem Res 32 1329 1335 1:CAS:528:DC%2BD2sXmvVyqtbo%3D 17401652 10.1007/s11064-007-9308-y (Pubitemid 46988193)
132. V. Srinivasan S.R. Pandi-Perumal G.J. Maestroni A.I. Esquifino, et al. 2005 Role of melatonin in neurodegenerative diseases Neurotox Res 7 293 318 1:CAS:528:DC%2BD28XhtFKqsbbP 16179266 10.1007/BF03033887
133. J.Z. Wang Z.F. Wang 2006 Role of melatonin in Alzheimer-like neurodegeneration Acta Pharmacol Sin 27 41 49 16364209 10.1111/j.1745-7254.2006. 00260.x 1:CAS:528:DC%2BD28XktlKitQ%3D%3D (Pubitemid 43051944)
134. A. Gupta K. Pansari 2003 Inflammation and Alzheimer's disease Int J Clin Pract 57 36 39 1:STN:280:DC%2BD3s%2Fns1KmsQ%3D%3D 12587940 (Pubitemid 36181746)
135. B.A. in t' Veld A. Ruitenberg A. Hofman, et al. 2001 Nonsteroidal antiinflammatory drugs and the risk of Alzheimer's disease N Engl J Med 345 1515 1521 10.1056/NEJMoa010178 (Pubitemid 33144916)
136. P.P. Zandi J.C. Anthony K.M. Hayden, et al. 2002 Reduced incidence of AD with NSAID but not H2 receptor antagonists: the Cache County Study Neurology 59 880 886 1:CAS:528:DC%2BD38XntVynsLc%3D 12297571
137. C.A. Szekely J.C. Breitner A.L. Fitzpatrick, et al. 2008 NSAID use and dementia risk in the Cardiovascular Health Study: role of APOE and NSAID type Neurology 70 17 24 1:CAS:528:DC%2BD2sXhsVGgtbfN 18003940 10.1212/01.wnl. 0000284596.95156.48
138. J. Rogers L.C. Kirby S.R. Hempelman, et al. 1993 Clinical trial of indomethacin in Alzheimer's disease Neurology 43 1609 1611 1:STN:280: DyaK3szlsVGrtw%3D%3D 8351023 (Pubitemid 23230557)
139. Tabet N, Feldman H. Indomethacin for Alzheimer's disease. Cochrane Database of Systematic Reviews 2002;2:CD003673.
140. D. de Jong R. Jansen W. Hoefnagels, et al. 2008 No effect of one-year treatment with indomethacin on Alzheimer's disease progression: a randomized controlled trial PLoS ONE. 3 e1475 18213383 10.1371/journal.pone.0001475 (Pubitemid 351796317)
141. Tabet N, Feldmand H. Ibuprofen for Alzheimer's disease. Cochrane Database Syst Rev. 2003;2:CD004031.
142. S.A. Reines G.A. Block J.C. Morris, et al. 2004 Rofecoxib: no effect on Alzheimer's disease in a 1-year, randomized, blinded, controlled study Neurology 62 66 71 1:CAS:528:DC%2BD3sXhtVWjtrrL 14718699 (Pubitemid 38082872)
143. H. Soininen C. West J. Robbins, et al. 2007 Long-term efficacy and safety of celecoxib in Alzheimer's disease Dement Geriatr Cogn Disord 23 8 21 1:CAS:528:DC%2BD28XhtlSrsLvP 17068392 10.1159/000096588 (Pubitemid 46005786)
144. P.S. Aisen K.A. Schafer M. Grundman, et al. 2003 Effects of rofecoxib or naproxen vs placebo on Alzheimer disease progression: a randomized controlled trial JAMA 289 2819 2826 1:CAS:528:DC%2BD3sXktlKmsb0%3D 12783912 10.1001/jama.289.21.2819 (Pubitemid 37430117)
145. H. Geerts 2007 Drug evaluation: (R)-flurbiprofen-an enantiomer of flurbiprofen for the treatment of Alzheimer's disease IDrugs 10 121 133 1:CAS:528:DC%2BD2sXjtF2jtr4%3D 17285465 (Pubitemid 46438443)
146. S. Brode A. Cooke 2008 Immune-potentiating effects of the chemotherapeutic drug cyclophosphamide Crit Rev Immunol 28 109 126 1:CAS:528:DC%2BD1cXmtFKhs7c%3D 18540827 (Pubitemid 351507425)
147. E.L. Tobinick H. Gross 2008 Rapid cognitive improvement in Alzheimer's disease following perispinal etanercept administration J Neuroinflammation 5 2 18184433 10.1186/1742-2094-5-2 1:CAS:528:DC%2BD1cXkvVCqtbk%3D (Pubitemid 351149918)
148. K.B. Harikumar B.B. Aggarwal 2008 Resveratrol: a multitargeted agent for age-associated chronic diseases Cell Cycle 7 1020 1035 1:CAS:528: DC%2BD1cXnvVSrsLY%3D 18414053 10.4161/cc.7.8.5740
149. F. Yang G.P. Lim A.N. Begum, et al. 2005 Curcumin inhibits formation of amyloid beta oligomers and fibrils, binds plaques, and reduces amyloid in vivo J Biol Chem 280 5892 5901 1:CAS:528:DC%2BD2MXhtlClt7w%3D 15590663 10.1074/jbc.M404751200 (Pubitemid 40280072)
150. J.T. Greenamyre A.B. Young 1989 Excitatory amino acids and Alzheimer's disease Neurobiol Aging 10 593 602 1:CAS:528:DyaL1MXmtFalsLY%3D 2554168 10.1016/0197-4580(89)90143-7 (Pubitemid 19245482)
151. M.O. Chohan K. Iqbal 2006 From tau to toxicity: emerging roles of NMDA receptor in Alzheimer's disease J Alzheimers Dis 10 81 87 1:CAS:528: DC%2BD28XpsValtbw%3D 16988485 (Pubitemid 44401369)
152. C.G. Parsons A. Stöffler W. Danysz 2007 Memantine: a NMDA receptor antagonist that improves memory by restoration of homeostasis in the glutamatergic system-too little activation is bad, too much is even worse Neuropharmacology 53 699 723 1:CAS:528:DC%2BD2sXhtFGrsLzF 17904591 10.1016/j.neuropharm.2007.07.013 (Pubitemid 47532143)
153. M.R. Farlow 2004 NMDA receptor antagonists A new therapeutic approach for Alzheimer's disease. Geriatrics 59 22 27
154. S.A. Lipton 2007 Pathologically-activated therapeutics for neuroprotection: mechanism of NMDA receptor block by memantine and S-nitrosylation Curr Drug Targets 8 621 632 1:CAS:528:DC%2BD2sXlsVWmurc%3D 17504105 10.2174/138945007780618472 (Pubitemid 46785060)
155. P.R. Zoladz A.M. Campbell C.R. Park, et al. 2006 Enhancement of long-term spatial memory in adult rats by the noncompetitive NMDA receptor antagonists, memantine and neramexane Pharmacol Biochem Behav 85 298 306 1:CAS:528: DC%2BD28XhtlarsrnP 17045636 10.1016/j.pbb.2006.08.011 (Pubitemid 44881071)
156. E. Dicou C.M. Rangon F. Guimiot, et al. 2003 Positive allosteric modulators of AMPA receptors are neuroprotective against lesions induced by an NMDA agonist in neonatal mouse brain Brain Res 970 221 225 1:CAS:528: DC%2BD3sXivFeqtbk%3D 12706264 10.1016/S0006-8993(03)02357-6 (Pubitemid 36423198)
157. J.C. Quirk E.S. Nisenbaum 2002 LY404187: a novel positive allosteric modulator of AMPA receptors CNS Drug Rev 8 255 282 1:CAS:528: DC%2BD38Xoslymtrc%3D 12353058 10.1111/j.1527-3458.2002.tb00228.x (Pubitemid 35191286)
158. A.S. Chappell C. Gonzales J. Williams, et al. 2007 AMPA potentiator treatment of cognitive deficits in Alzheimer disease Neurology 68 1008 1012 1:CAS:528:DC%2BD2sXjtFynt7s%3D 17389305 10.1212/01.wnl.0000260240.46070.7c (Pubitemid 46569134)
159. http://www.clinicaltrials.gov. (accessed 15 december 2010).
160. F. Fumagalli G. Racagni M.A. Riva 2006 The expanding role of BDNF: a therapeutic target for Alzheimer's disease? Pharmacogenomics J 6 8 15 1:CAS:528:DC%2BD28XjtVyltg%3D%3D 16314887 10.1038/sj.tpj.6500337 (Pubitemid 43118305)
161. J.M. Conner M.A. Darracq J. Roberts, et al. 2001 Nontropic actions of neurotrophins: subcortical nerve growth factor gene delivery reverses age-related degeneration of primate cortical cholinergic innervation Proc Natl Acad Sci U S A 98 1941 1946 1:CAS:528:DC%2BD3MXhsVWitr4%3D 11172055 10.1073/pnas.98.4.1941 (Pubitemid 32165602)
162. S. Capsoni S. Giannotta A. Cattaneo 2002 Nerve growth factor and galantamine ameliorate early signs of neurodegeneration in anti-nerve growth factor mice Proc Natl Acad Sci U S A 99 12432 12437 1:CAS:528: DC%2BD38XntlCktrs%3D 12205295 10.1073/pnas.192442999
163. M.H. Tuszynski L. Thal M. Pay, et al. 2005 A phase 1 clinical trial of nerve growth factor gene therapy for Alzheimer disease Nat Med 11 551 555 1:CAS:528:DC%2BD2MXjvVOls7s%3D 15852017 10.1038/nm1239 (Pubitemid 40691288)
164. M. Grundman E. Capparelli H.T. Kim, et al. 2003 A multicenter, randomized, placebo controlled, multiple-dose, safety and pharmacokinetic study of AIT-082 (Neotrofin) in mild Alzheimer's disease patients Life Sci 73 539 553 1:CAS:528:DC%2BD3sXktVOrtbY%3D 12770610 (Pubitemid 36603333)
165. K. Sugaya A. Alvarez A. Marutle, et al. 2006 Stem cell strategies for Alzheimer's disease therapy Panminerva Med 48 87 96 1:STN:280: DC%2BD28rivVymtA%3D%3D 16953146 (Pubitemid 44671264)
166. A.A. Oliveira Jr H.M. Hodges 2005 Alzheimer's disease and neural transplantation as prospective cell therapy Curr Alzheimer Res 2 79 95 1:CAS:528:DC%2BD2MXhsFegtbw%3D 15977991 10.2174/1567205052772759 (Pubitemid 41397968)
167. G.A. Elder R. De Gasperi M.A. Gama Sosa 2006 Research update: neurogenesis in adult brain and neuropsychiatric disorders Mt Sinai J Med 73 931 940 17195878 (Pubitemid 46040390)
168. M.A. Lovell H. Geiger G.E. Van Zant, et al. 2006 Isolation of neural precursor cells from Alzheimer's disease and aged control postmortem brain Neurobiol Aging 27 909 917 15979211 10.1016/j.neurobiolaging.2005.05.004 (Pubitemid 44262274)
169. V. Pagocic P. Herrling 2007 List of drugs in development for neurodegenerative diseases Neurodegenerative Dis 4 443 486 10.1159/000107705 1:CAS:528:DC%2BD2sXhtFKitrjE
170. T.M. Rees S. Brimijoin 2003 The role of acetylcholinesterase in the pathogenesis of Alzheimer's disease Drugs Today (Barc) 39 75 83 1:CAS:528:DC%2BD3sXjt1ajs7o%3D 10.1358/dot.2003.39.1.740206 (Pubitemid 36378463)
171. C.G. Ballard N.H. Greig A.L. Guillozet-Bongaarts, et al. 2005 Cholinesterases: roles in the brain during health and disease Curr Alzheimer Res 2 307 318 1:CAS:528:DC%2BD2MXmtFKquro%3D 15974896 10.2174/1567205054367838 (Pubitemid 40980189)
172. E. Mori M. Hashimoto K.R. Krishnan, et al. 2006 What constitutes clinical evidence for neuroprotection in Alzheimer disease: support for the cholinesterase inhibitors? Alzheimer Dis Assoc Disord 20 S19 S26 1:CAS:528:DC%2BD28XlsFeju7Y%3D 16772752 10.1097/01.wad.0000213805.66811.31 (Pubitemid 44305905)
173. H.Y. Zhang X.C. Tang 2006 Neuroprotective effects of huperzine A: new therapeutic targets for neurodegenerative disease Trends Pharmacol Sci 27 619 625 1:CAS:528:DC%2BD28Xht1eku7fK 17056129 10.1016/j.tips.2006.10.004 (Pubitemid 44738090)
174. Li J, Wu HM, Zhou RL, et al. Huperzine A for Alzheimer's disease. Cochrane Database Syst Rev 2008;2:CD005592.
175. R. Wang X.C. Tang 2005 Neuroprotective effects of huperzine A A natural cholinesterase inhibitor for the treatment of Alzheimer's disease. Neurosignals 14 71 82 1:CAS:528:DC%2BD2MXlt1Smsrs%3D
176. N.H. Greig K. Sambamurti Q.S. Yu, et al. 2005 An overview of phenserine tartrate, a novel acetylcholinesterase inhibitor for the treatment of Alzheimer's disease Curr Alzheimer Res 2 281 290 1:CAS:528:DC%2BD2MXmtFKqur8%3D 15974893 10.2174/1567205054367829 (Pubitemid 40980186)
177. A. Kadir N. Andreasen O. Almkvist, et al. 2008 Effect of phenserine treatment on brain functional activity and amyloid in Alzheimer's disease Ann Neurol 63 621 631 1:CAS:528:DC%2BD1cXntFyrtrc%3D 18300284 10.1002/ana.21345
178. D.K. Lahiri D. Chen B. Maloney, et al. 2007 The experimental Alzheimer's disease drug posiphen [(+)-phenserine] lowers amyloid-beta peptide levels in cell culture and mice J Pharmacol Exp Ther 320 386 396 1:CAS:528: DC%2BD2sXjsFChtg%3D%3D 17003227 10.1124/jpet.106.112102 (Pubitemid 46025753)
179. J. Klein 2007 Phenserine Expert Opin Investig Drugs 16 1087 1097 1:CAS:528:DC%2BD2sXmvVOmtr8%3D 17594192 10.1517/13543784.16.7.1087 (Pubitemid 47074163)
180. R.M. Lane S.G. Potkin A. Enz 2006 Targeting acetylcholinesterase and butyrylcholinesterase in dementia Int J Neuropsychopharmacol 9 101 124 1:CAS:528:DC%2BD28Xht1ehtw%3D%3D 16083515 10.1017/S1461145705005833 (Pubitemid 43068340)
181. M.A. Kamal A.A. Al-Jafari Q.S. Yu, et al. 2006 Kinetic analysis of the inhibition of human butyrylcholinesterase with cymserine Biochim Biophys Acta 1760 200 206 1:CAS:528:DC%2BD28XitVarsL0%3D 16309845 (Pubitemid 43320508)
182. M.A. Kamal P. Klein Q.S. Yu, et al. 2006 Kinetics of human serum butyrylcholinesterase and its inhibition by a novel experimental Alzheimer therapeutic, bisnorcymserine J Alzheimers Dis 10 43 51 1:CAS:528: DC%2BD28XpsValt7s%3D 16988481 (Pubitemid 44401365)
183. L.J. Thal M. Forrest H. Loft, et al. 2000 Lu 25-109, a muscarinic agonist, fails to improve cognition in Alzheimer's disease Neurology 54 421 426 1:CAS:528:DC%2BD3cXhtV2ns7g%3D 10668706 (Pubitemid 30078076)
184. W.S. Messer Jr. 2002 The utility of muscarinic agonists in the treatment of Alzheimer's disease J Mol Neurosci 19 187 193 1:CAS:528:DC%2BD38XmvFCqu7k%3D 12212779 10.1007/s12031-002-0031-5 (Pubitemid 35013354)
185. A. isher Z. Pittel R. Haring, et al. 2003 M1 muscarinic agonists can modulate some of the hallmarks in Alzheimer's disease: implications in future therapy J Mol Neurosci 20 349 356 10.1385/JMN:20:3:349 (Pubitemid 38146993)
186. A. Caccamo S. Oddo L.M. Billings, et al. 2006 M1 receptors play a central role in modulating AD-like pathology in transgenic mice Neuron 49 671 682 1:CAS:528:DC%2BD28Xis1Gitr4%3D 16504943 10.1016/j.neuron.2006.01.020 (Pubitemid 43290127)
187. M. Wienrich D. Meier H.A. Ensinger, et al. 2001 Pharmacodynamic profile of the M1 agonist talsaclidine in animals and man Life Sci 68 2593 2600 1:CAS:528:DC%2BD3MXjs1Wks7Y%3D 11392631 10.1016/S0024-3205(01)01057-8 (Pubitemid 32455699)
188. C. Hock A. Maddalena A. Raschig, et al. 2003 Treatment with the selective muscarinic m1 agonist talsaclidine decreases cerebrospinal fluid levels of A beta 42 in patients with Alzheimer's disease Amyloid 10 1 6 1:CAS:528: DC%2BD3sXktlKitL8%3D 12762134 (Pubitemid 36520922)
189. S.P. Arneric J.P. Sullivan M.W. Decker, et al. 1995 Potential treatment of Alzheimer disease using cholinergic channel activators (ChCAs) with cognitive enhancement, anxiolytic-like, and cytoprotective properties Alzheimer Dis Assoc Disord 9 50 61 8534424 10.1097/00002093-199501002-00009
190. P.M. Lippiello M. Bencherif J.A. Gray, et al. 1996 RJR-2403: a nicotinic agonist with CNS selectivity II. In vivo characterization J Pharmacol Exp Ther 279 1422 1429 1:CAS:528:DyaK2sXntVeg 8968367 (Pubitemid 27166791)
191. M. Bencherif A.J. Bane C.H. Miller, et al. 2000 TC-2559: a novel orally active ligand selective at neuronal acetylcholine receptors Eur J Pharmacol 409 45 55 1:CAS:528:DC%2BD3cXotlGjurg%3D 11099699 10.1016/S0014-2999(00)00807-4
192. P. Lippiello S.R. Letchworth G.J. Gatto, et al. 2006 Ispronicline: a novel alpha4beta2 nicotinic acetylcholine receptor-selective agonist with cognition-enhancing and neuroprotective properties J Mol Neurosci 30 19 20 1:CAS:528:DC%2BD28XhtlWgtbfF 17192610 10.1385/JMN:30:1:19 (Pubitemid 46035302)
193. N.H. Lin D.E. Gunn K.B. Ryther, et al. 1997 Structure-activity studies on 2-methyl-3-(2(S)-pyrrolidinylmethoxy) pyridine (ABT-089): an orally bioavailable 3-pyridyl ether nicotinic acetylcholine receptor ligand with cognition-enhancing properties J Med Chem 40 385 390 1:CAS:528: DyaK2sXktFCqsg%3D%3D 9022806 10.1021/jm960233u (Pubitemid 27081974)
194. L.E. Rueter D.J. Anderson C.A. Briggs, et al. 2004 ABT-089: pharmacological properties of a neuronal nicotinic acetylcholine receptor agonist for the potential treatment of cognitive disorders CNS Drug Rev 10 167 182 1:CAS:528:DC%2BD2cXmtlCntL0%3D 15179445 10.1111/j.1527-3458.2004.tb00011.x (Pubitemid 38879109)
195. W.R. Kem 2000 The brain alpha7 nicotinic receptor may be an important therapeutic target for the treatment of Alzheimer's disease: studies with DMXBA (GTS-21) Behav Brain Res 113 169 181 1:CAS:528:DC%2BD3cXlvFGmsbc%3D 10942043 10.1016/S0166-4328(00)00211-4 (Pubitemid 30645554)
196. G.C. Dunbar F. Inglis R. Kuchibhatla, et al. 2007 Effect of ispronicline, a neuronal nicotinic acetylcholine receptor partial agonist, in subjects with age associated memory impairment (AAMI) J Psychopharmacol 21 171 178 1:CAS:528:DC%2BD2sXkt1Wksb8%3D 17329297 10.1177/0269881107066855 (Pubitemid 46280469)
197. J.D. Williamson M.E. Miller R.N. Bryan, et al. 2007 The Action to Control Cardiovascular Risk in Diabetes Memory in Diabetes Study (ACCORD-MIND): rationale, design, and methods Am J Cardiol 99 112 122 10.1016/j.amjcard.2007. 03.029 (Pubitemid 46961889)
198. E. Rönnemaa B. Zethelius J. Sundelöf, et al. 2008 Impaired insulin secretion increases the risk of Alzheimer disease Neurology 71 1065 1071 18401020 10.1212/01.wnl.0000310646.32212.3a 1:CAS:528:DC%2BD1cXhtFCisbvK
199. B. Sabayan F. Foroughinia A. Mowla, et al. 2008 Role of Insulin Metabolism Disturbances in the Development of Alzheimer Disease: Mini Review Am J Alzheimers Dis Other Demen 23 192 199 18198237 10.1177/1533317507312623 (Pubitemid 351550911)
200. S. Craft 2007 Insulin resistance and Alzheimer's disease pathogenesis: potential mechanisms and implications for treatment Curr Alzheimer Res 4 147 152 1:CAS:528:DC%2BD2sXksVWkt70%3D 17430239 10.2174/156720507780362137 (Pubitemid 46557503)
201. L. Gasparini G.K. Gouras R. Wang, et al. 2001 Stimulation of beta-amyloid precursor protein trafficking by insulin reduces intraneuronal beta-amyloid and requires mitogen-activated protein kinase signaling J Neurosci 21 2561 2570 1:CAS:528:DC%2BD3MXjtVWkurs%3D 11306609 (Pubitemid 32298198)
202. M.A. Reger G.S. Watson P.S. Green, et al. 2008 Intranasal insulin improves cognition and modulates beta-amyloid in early AD Neurology 70 440 448 1:CAS:528:DC%2BD1cXhtFels70%3D 17942819 10.1212/01.WNL.0000265401.62434.36
203. G.S. Watson S. Craft 2003 The role of insulin resistance in the pathogenesis of Alzheimer's disease: implications for treatment CNS Drugs 17 27 45 1:CAS:528:DC%2BD3sXms1Sjtw%3D%3D 12467491 10.2165/00023210-200317010-00003 (Pubitemid 36044347)
204. G.S. Watson B.A. Cholerton M.A. Reger, et al. 2005 Preserved cognition in patients with early Alzheimer disease and amnestic mild cognitive impairment during treatment with rosiglitazone: a preliminary study Am J Geriatr Psychiatry 13 950 958 16286438 (Pubitemid 46638661)
205. S.E. Nissen K. Wolski 2007 Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes N Engl J Med 356 2457 2471 1:CAS:528:DC%2BD2sXms1SisrY%3D 17517853 10.1056/NEJMoa072761 (Pubitemid 46919772)
206. M.A. Reger S.T. Henderson C. Hale, et al. 2004 Effects of beta-hydroxybutyrate on cognition in memory-impaired adults Neurobiol Aging 25 311 314 1:CAS:528:DC%2BD2cXhtV2ksbk%3D 15123336 10.1016/S0197-4580(03)00087-3 (Pubitemid 38220966)
207. http://www.accerapharma.com (accessed 15 december 2008)
208. K. Yaffe G. Sawaya I. Lieberburg, et al. 1998 Estrogen therapy in postmenopausal women: effects on cognitive function and dementia JAMA 279 688 695 1:CAS:528:DyaK1cXhvVyks7o%3D 9496988 10.1001/jama.279.9.688 (Pubitemid 28138739)
209. E. Hogervorst J. Williams M. Budge, et al. 2000 The nature of the effect of female gonadal hormone replacement therapy on cognitive function in post-menopausal women: a meta-analysis Neuroscience 101 485 512 1:CAS:528:DC%2BD3cXosFemsbg%3D 11113299 10.1016/S0306-4522(00)00410-3
210. A. LeBlanc 2002 Estrogen and Alzheimer's disease Curr Opin Investig Drugs 3 768 773 1:CAS:528:DC%2BD38XlvVShu7Y%3D 12090551
211. P. Maki E. Hogervorst 2003 The menopause and HRT. HRT and cognitive decline Best Pract Res Clin Endocrinol Metab 17 105 122 1:CAS:528: DC%2BD3sXjsVOgtb4%3D 12763515 10.1016/S1521-690X(02)00082-9
212. K.M. Webber G. Perry M.A. Smith, et al. 2007 The contribution of luteinizing hormone to Alzheimer disease pathogenesis Clin Med Res 5 177 183 1:CAS:528:DC%2BD1cXjs1emsb0%3D 18056027 10.3121/cmr.2007.741 (Pubitemid 351303232)
213. K.M. Webber G. Casadesus C.S. Atwood, et al. 2007 Gonadotropins: a cohesive gender-based etiology of Alzheimer disease Mol Cell Endocrinol 260-262 271 275 17052835 10.1016/j.mce.2006.01.018 1:CAS:528:DC%2BD28Xht1eqtL%2FE (Pubitemid 44792341)
214. R.A. Short R.L. Bowen P.C. O'Brien, et al. 2001 Elevated gonadotropin levels in patients with Alzheimer disease Mayo Clin Proc 76 906 909 1:CAS:528:DC%2BD3MXntFCnt7s%3D 11560301 10.4065/76.9.906 (Pubitemid 32825912)
215. R.L. Bowen M.A. Smith P.L. Harris, et al. 2002 Elevated luteinizing hormone expression colocalizes with neurons vulnerable to Alzheimer's disease pathology J Neurosci Res 70 514 518 1:CAS:528:DC%2BD38XosVejsrg%3D 12391612 10.1002/jnr.10452 (Pubitemid 35222388)
216. G. Casadesus M.R. Garrett K.M. Webber, et al. 2006 The estrogen myth: potential use of gonadotropin-releasing hormone agonists for the treatment of Alzheimer's disease Drugs R D 7 187 193 1:CAS:528:DC%2BD28XntlantL4%3D 16752944 10.2165/00126839-200607030-00004 (Pubitemid 43886276)
217. S.V. Meethal M.A. Smith R.L. Bowen, et al. 2005 The gonadotropin connection in Alzheimer's disease Endocrine 26 317 326 1:CAS:528: DC%2BD2MXosVCms7w%3D 16034187 10.1385/ENDO:26:3:317 (Pubitemid 41271098)
218. M.M. Cherrier A.M. Matsumoto J.K. Amory, et al. 2005 Testosterone improves spatial memory in men with Alzheimer disease and mild cognitive impairment Neurology 64 2063 2068 1:CAS:528:DC%2BD2MXkvVOlsbs%3D 15985573 10.1212/01.WNL.0000165995.98986.F1 (Pubitemid 40880994)
219. P.H. Lu D.A. Masterman R. Mulnard, et al. 2006 Effects of testosterone on cognition and mood in male patients with mild Alzheimer disease and healthy elderly men Arch Neurol 63 177 185 16344336 10.1001/archneur.63.2.nct50002 (Pubitemid 43261728)
220. M.M. Cherrier S. Asthana S. Plymate, et al. 2001 Testosterone supplementation improves spatial and verbal memory in healthy older men Neurology 57 80 88 1:CAS:528:DC%2BD3MXlsFKnurg%3D 11445632 (Pubitemid 32634854)
221. M.M. Cherrier A.M. Matsumoto J.K. Amory, et al. 2005 The role of aromatization in testosterone supplementation: effects on cognition in older men Neurology 64 290 296 1:CAS:528:DC%2BD2MXkvVOlsbs%3D 15668427 10.1212/01.WNL.0000165995.98986.F1 (Pubitemid 40880994)
222. G.R. Merriam R.S. Schwartz M.V. Vitiello 2003 Growth hormone-releasing hormone and growth hormone secretagogues in normal aging Endocrine 22 41 48 1:CAS:528:DC%2BD3sXovVGqt7w%3D 14610297 10.1385/ENDO:22:1:41 (Pubitemid 37390848)
223. M.V. Vitiello K.E. Moe G.R. Merriam, et al. 2006 Growth hormone releasing hormone improves the cognition of healthy older adults Neurobiol Aging 27 318 323 1:CAS:528:DC%2BD28XitFCktg%3D%3D 16399214 10.1016/j.neurobiolaging.2005.01. 010 (Pubitemid 43038556)
224. J.J. Sevigny J.M. Ryan C.H. van Dyck, et al. 2008 Growth hormone secretagogue MK-677: no clinical effect on AD progression in a randomized trial Neurology. 18;71 21 1702 1708 10.1212/01.wnl.0000335163.88054.e7 1:CAS:528:DC%2BD1cXhtlGls7bM
225. C. Hibberd J.L. Yau J.R. Seckl 2000 Glucocorticoids and the ageing hippocampus J Anat 197 553 562 1:CAS:528:DC%2BD3MXps1Wnug%3D%3D 11197528 10.1046/j.1469-7580.2000.19740553.x (Pubitemid 32051535)
226. K.N. Green L.M. Billings B. Roozendaal, et al. 2006 Glucocorticoids increase amyloid-beta and tau pathology in a mouse model of Alzheimer's disease J Neurosci 26 9047 9056 1:CAS:528:DC%2BD28Xpt1aqu7w%3D 16943563 10.1523/JNEUROSCI.2797-06.2006 (Pubitemid 44319396)
227. V. Dhikav K.S. Anand 2007 Glucocorticoids may initiate Alzheimer's disease: a potential therapeutic role for mifepristone (RU-486) Med Hypotheses 68 1088 1092 1:CAS:528:DC%2BD2sXit12mu7o%3D 17107752 10.1016/j.mehy.2006.09.038
228. N. Pomara P.M. Doraiswamy H. Tun, et al. 2002 Mifepristone (RU 486) for Alzheimer's disease Neurology 58 1436 12011303
229. C. DeBattista J. Belanoff 2005 C-1073 (mifepristone) in the adjunctive treatment of Alzheimer's disease Curr Alzheimer Res 2 125 129 1:CAS:528:DC%2BD2MXltVantr8%3D 15974908 10.2174/1567205053585954 (Pubitemid 40867291)
230. V.A. Komater M.J. Buckley K.E. Browman, et al. 2005 Effects of histamine H3 receptor antagonists in two models of spatial learning Behav Brain Res 159 295 300 1:CAS:528:DC%2BD2MXjt1Kjsbs%3D 15817192 10.1016/j.bbr.2004.11.008 (Pubitemid 40462505)
231. A.D. Medhurst A.R. Atkins I.J. Beresford, et al. 2007 GSK189254, a novel H3 receptor antagonist that binds to histamine H3 receptors in Alzheimer's disease brain and improves cognitive performance in preclinical models J Pharmacol Exp Ther 321 1032 1045 1:CAS:528:DC%2BD2sXmsFeqs74%3D 17327487 10.1124/jpet.107.120311 (Pubitemid 46762709)
232. S. Bachurin E. Bukatina N. Lermontova, et al. 2001 Antihistamine agent Dimebon as a novel neuroprotector and a cognition enhancer Ann N Y Acad Sci 939 425 435 1:CAS:528:DC%2BD3MXlsV2ksbw%3D 11462798 10.1111/j.1749-6632.2001. tb03654.x (Pubitemid 32620096)
233. R.S. Doody S.I. Gavrilova M. Sano, et al. 2008 Effect of dimebon on cognition, activities of daily living, behaviour, and global function in patients with mild-to-moderate Alzheimer's disease: a randomised, double-blind, placebo-controlled study Lancet 372 207 215 1:CAS:528:DC%2BD1cXoslWktrc%3D 18640457 10.1016/S0140-6736(08)61074-0 (Pubitemid 351978110)
234. L. Truchot S.N. Costes L. Zimmer, et al. 2007 Up-regulation of hippocampal serotonin metabolism in mild cognitive impairment Neurology 69 1012 1017 1:CAS:528:DC%2BD2sXpsFaju70%3D 17785670 10.1212/01.wnl.0000271377.52421.4a (Pubitemid 47366055)
235. S. Raje A.A. Patat V. Parks, et al. 2008 A positron emission tomography study to assess binding of lecozotan, a novel 5-hydroxytryptamine-1A silent antagonist, to brain 5-HT1A receptors in healthy young and elderly subjects, and in patients with Alzheimer's disease Clin Pharmacol Ther 83 86 96 1:CAS:528:DC%2BD2sXhsVylt7bF 17507923 10.1038/sj.clpt.6100232
236. W.E. Childers Jr M.A. Abou-Gharbia M.G. Kelly, et al. 2005 Synthesis and biological evaluation of benzodioxanylpiperazine derivatives as potent serotonin 5-HT(1A) antagonists: the discovery of Lecozotan J Med Chem 48 3467 3470 1:CAS:528:DC%2BD2MXjtlWnu70%3D 15887953 10.1021/jm049493z (Pubitemid 40664096)
237. L.E. Schechter D.L. Smith S. Rosenzweig-Lipson, et al. 2005 Lecozotan (SRA-333): a selective serotonin 1A receptor antagonist that enhances the stimulated release of glutamate and acetylcholine in the hippocampus and possesses cognitive-enhancing properties J Pharmacol Exp Ther 314 1274 1289 1:CAS:528:DC%2BD2MXpvFSqsbw%3D 15951399 10.1124/jpet.105.086363 (Pubitemid 41205994)
238. C. Labie C. Lafon C. Marmouget, et al. 1999 Effect of the neuroprotective compound SR57746A on nerve growth factor synthesis in cultured astrocytes from neonatal rat cortex Br J Pharmacol 127 139 144 1:CAS:528:DyaK1MXjtVGltrs%3D 10369466 10.1038/sj.bjp.0702545 (Pubitemid 29213242)
239. B.P. Kennedy M.G. Ziegler M. Alford, et al. 2003 Early and persistent alterations in prefrontal cortex MAO A and B in Alzheimer's disease J Neural Transm 110 789 801 1:CAS:528:DC%2BD3sXks1ajsrg%3D 12811639 (Pubitemid 36783232)
240. M.B. Youdim 2006 The path from anti Parkinson drug selegiline and rasagiline to multifunctional neuroprotective anti Alzheimer drugs ladostigil and m30 Curr Alzheimer Res 3 541 550 1:CAS:528:DC%2BD28XhtlWksbrF 17168653 10.2174/156720506779025288 (Pubitemid 46066429)
241. A.S. Khachaturian P.P. Zandi C.G. Lyketsos, et al. 2006 Antihypertensive medication use and incident Alzheimer disease: the Cache County Study Arch Neurol 63 686 692 16533956 10.1001/archneur.63.5.noc60013
242. P.G. Kehoe G.K. Wilcock 2007 Is inhibition of the renin-angiotensin system a new treatment option for Alzheimer's disease? Lancet Neurol 6 373 378 1:CAS:528:DC%2BD2sXkt12gu7g%3D 17362841 10.1016/S1474-4422(07)70077-7 (Pubitemid 46389616)
243. M.L. Hemming D.J. Selkoe W. Farris 2007 Effects of prolonged angiotensin-converting enzyme inhibitor treatment on amyloid beta-protein metabolism in mouse models of Alzheimer disease Neurobiol Dis 26 273 281 1:CAS:528:DC%2BD2sXjsVGhsL4%3D 17321748 10.1016/j.nbd.2007.01.004 (Pubitemid 46436503)
244. F. Forette M.L. Seux J.A. Staessen, et al. 2002 The prevention of dementia with antihypertensive treatment: new evidence from the Systolic Hypertension in Europe (Syst-Eur) study Arch Intern Med 162 2046 2052 12374512 10.1001/archinte.162.18.2046 (Pubitemid 35168212)
245. S. Yasar M. Corrada R. Brookmeyer, et al. 2005 Calcium channel blockers and risk of AD: the Baltimore Longitudinal Study of Aging Neurobiol Aging 26 157 163 1:CAS:528:DC%2BD2cXhtVCltb%2FO 15582745 10.1016/j.neurobiolaging.2004.03. 009 (Pubitemid 39600576)
246. López-Arrieta JM, Birks J. Nimodipine for primary degenerative, mixed and vascular dementia. Cochrane Database Syst Rev 2002;3:CD000147.
247. M.S. Morris 2003 Homocysteine and Alzheimer's disease Lancet Neurol 2 425 428 1:CAS:528:DC%2BD3sXms1yhsbw%3D 12849121 10.1016/S1474-4422(03)00438-1 (Pubitemid 36793935)
248. S. Seshadri 2006 Elevated plasma homocysteine levels: risk factor or risk marker for the development of dementia and Alzheimer's disease? J Alzheimers Dis 9 393 398 1:CAS:528:DC%2BD28XotFKgs74%3D 16917147 (Pubitemid 44253353)
249. P.S. Aisen L.S. Schneider M. Sano, et al. 2008 High-dose B vitamin supplementation and cognitive decline in Alzheimer disease: a randomized controlled trial JAMA 300 1774 1783 1:CAS:528:DC%2BD1cXht1GqtLnE 18854539 10.1001/jama.300.15.1774
250. A. Chan T.B. Shea 2007 Folate deprivation increases presenilin expression, gammasecretase activity, and Abeta levels in murine brain: potentiation by ApoE deficiency and alleviation by dietary S-adenosyl methionine J Neurochem 102 753 760 1:CAS:528:DC%2BD2sXovVyisr8%3D 17504266 10.1111/j.1471-4159.2007.04589.x (Pubitemid 47057297)
251. V. Pogacic P. Herrling 2007 list of drugs in development for neurodegenerative diseases Neurodegenerative Dis 4 443 486 1:CAS:528: DC%2BD2sXhtFKitrjE 10.1159/000107705
252. F. Mangialasche A. Solomon B. Winblad P. Mecocci M. Kivipelto 2010 Alzheimer's disease: clinical trials and drug development Lancet Neurol 9 7 702 716 1:CAS:528:DC%2BC3cXpsFajur8%3D 20610346 10.1016/S1474-4422(10)70119-8